SG11201805990XA - Means and methods for staging, typing and treating a cancerous disease - Google Patents

Means and methods for staging, typing and treating a cancerous disease

Info

Publication number
SG11201805990XA
SG11201805990XA SG11201805990XA SG11201805990XA SG11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA
Authority
SG
Singapore
Prior art keywords
international
regensburg
cancerous disease
methods
staging
Prior art date
Application number
SG11201805990XA
Inventor
Christoph Klein
Sebastian Scheitler
Melanie Werner-Klein
Martin Hoffmann
Isabelle Hodak
Original Assignee
Fraunhofer Ges Forschung
Univ Regensburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Ges Forschung, Univ Regensburg filed Critical Fraunhofer Ges Forschung
Publication of SG11201805990XA publication Critical patent/SG11201805990XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 August 2017 (03.08.2017) WIPO I PCT (10) International Publication Number WO 2017/129753 Al 11111111111111011101111111111101011111011101110111111011111101101111111110111111 (51) International Patent Classification: C12Q 1/68 (2006.01) (21) International Application Number: PCT/EP2017/051789 (22) International Filing Date: 27 January 2017 (27.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16152883.1 27 January 2016 (27.01.2016) EP (71) Applicants: FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. [DE/DE]; Hansastr. 27c, 80686 Miinchen (DE). UNI- VERSITAT REGENSBURG [DE/DE]; Universitasstr. 31, 93053 Regensburg (DE). (72) Inventors: KLEIN, Christoph; Eichenstr. 12a, 93049 Re- gensburg (DE). SCHEITLER, Sebastian; Martin-Gre- if-Str. 1, 93051 Regensburg (DE). WERNER-KLEIN, Melanie; Eichenstr. 12a, 93049 Regensburg (DE). HOFF- MANN, Martin; Alte Nilmberger Str. 30, 93059 Regens- burg (DE). HODAK, Isabelle; Jakob-Hagenbacher-Str. 10c, 80993 Miinchen (DE). = (74) Agent: MEIER, Jurgen; SiebertstraBe 3, 81675 Mlinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) W O 20 17 / 12975 3 Al (54) Title: MEANS AND METHODS FOR STAGING, TYPING AND TREATING A CANCEROUS DISEASE (57) : The present invention relates to methods for diagnosing, staging and treating cancer, in particular melanoma. In par , - ticular, the present invention provides methods for determining the stage/type of a cancerous disease, comprising detecting somatic alterations of the DNA of one or more disseminated cancer cells (DCCs), obtained after homing to a distant organ, such as lymph node; and determining the somatic evolution of the DCC(s) based on the detected somatic alterations, wherein the somatic evolution is indicative of the stage/type of the cancerous disease.
SG11201805990XA 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease SG11201805990XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16152883.1A EP3199641B1 (en) 2016-01-27 2016-01-27 Means and methods for staging, typing and treating a cancerous disease
PCT/EP2017/051789 WO2017129753A1 (en) 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease

Publications (1)

Publication Number Publication Date
SG11201805990XA true SG11201805990XA (en) 2018-08-30

Family

ID=55310656

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805990XA SG11201805990XA (en) 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease

Country Status (10)

Country Link
US (1) US11702701B2 (en)
EP (2) EP3199641B1 (en)
JP (1) JP2019508032A (en)
KR (1) KR20180102674A (en)
CN (1) CN108770360B (en)
AU (1) AU2017211976B2 (en)
CA (1) CA3012404A1 (en)
ES (1) ES2905208T3 (en)
SG (1) SG11201805990XA (en)
WO (1) WO2017129753A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU755499B2 (en) 1998-09-18 2002-12-12 Micromet Ag DNA amplification of a single cell
WO2002037113A2 (en) * 2000-11-03 2002-05-10 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
ITRM20110149A1 (en) * 2011-03-25 2012-09-26 Massimo Zollo BIOMARATOR FOR DETECTION OF CIRCULATING CANCER CELLS AND RELATED METHODS AND DETECTION KITS.
US20140227692A1 (en) * 2011-07-08 2014-08-14 Deborah W. Neklason Methods of detecting hereditary cancer predisposition
WO2013086478A1 (en) * 2011-12-10 2013-06-13 Abbott Molecular Inc. Materials and methods for diagnosis of malignant melanoma and prognosis of metastasis of malignant melanoma
EP3033150A4 (en) * 2013-08-13 2017-06-28 Bionumerik Pharmaceuticals, Inc. Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
CA2931140C (en) 2014-02-05 2022-08-30 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Error-free sequencing of dna

Also Published As

Publication number Publication date
JP2019508032A (en) 2019-03-28
KR20180102674A (en) 2018-09-17
CA3012404A1 (en) 2017-08-03
WO2017129753A8 (en) 2017-10-19
AU2017211976A1 (en) 2018-08-02
CN108770360A (en) 2018-11-06
EP3408411A1 (en) 2018-12-05
EP3199641B1 (en) 2021-09-29
US20190062845A1 (en) 2019-02-28
WO2017129753A1 (en) 2017-08-03
EP3199641A1 (en) 2017-08-02
US11702701B2 (en) 2023-07-18
CN108770360B (en) 2022-06-14
AU2017211976B2 (en) 2022-09-22
ES2905208T3 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201809522WA (en) Method of nucleic acid sequence determination
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201908787WA (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201906553TA (en) Methods and reagents for synthesising polynucleotide molecules
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201809530PA (en) Method for recovery of phosphate
SG11201903428XA (en) Pluripotent stem cell assay
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201805497QA (en) Mutated truncated von willebrand factor
SG11201806825RA (en) A data source system agnostic fact category partitioned information repository and methods for the insertion and retrieval of data using the information repository
SG11201809413RA (en) Detection of chromosome interaction relevant to breast cancer
SG11201810914VA (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
SG11201905640XA (en) Oncogenic splice variant determination
SG11201809473QA (en) Humanized anti-basigin antibodies and the use thereof
SG11201809996QA (en) Ribonucleic acid (rna) interactions
SG11201805494WA (en) Mutated von willebrand factor
SG11201811258UA (en) Process for the production of a dna vaccine for cancer immunotherapy
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging